NDA 219908 · Celcuity
Revtorpyk
Gedatolisib · Intravenous · Kinase Inhibitor
NovelPriority reviewCDER novel approval, Jul 14, 2026: In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting
Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jul 14, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
2 Phase 3, 3 recruiting
FAERS reports
20
18 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 19, 2026.
REVTORPYK is indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting [see Dosage and Administration (2.1) and Clinical Studies (14) ] . REVTORPYK is a kinase inhibitor indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. (1)
Mechanism: Gedatolisib is a kinase inhibitor of class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2, resulting in downstream inhibition of multiple effectors, including AKT. In estrogen receptor (ER)-positive breast cancer cell lines and xenograft models harboring wild-type or mutant PIK3CA , gedatolisib induced apoptosis and anti-proliferative effects in vitro and reduced tumor cell growth in vivo . In a human ER-positive breast cancer xenograft model harboring a PIK3CA mutation, the combination of gedatolisib with palbociclib and fulvestrant increased tumor growth inhibition...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 14, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterReviewLabel
1 products under this application
- REVTORPYK · GEDATOLISIB 180MG/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gedatolisib" as an intervention, any sponsor and status, largest first.
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)Pivotal-lookingRecruiting
Celcuity IncIndustry
NCT06757634 · 1,180 participants (planned) · Start Jul 24, 2025 · Primary completion Mar 31, 2029
Drug: Arm A: Gedatolisib + Palbociclib + Fulvestrant; Arm B: Ribociclib + Fulvestrant and 2 more · For: Breast Cancer
Sites: Jonesboro, Arkansas; Little Rock, Arkansas; Duarte, California · 239 sites in all
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)Pivotal-lookingActive, not recruiting
Celcuity IncIndustry
NCT05501886 · 701 participants (planned) · Start Dec 8, 2022 · Primary completion Jun 30, 2026
Drug: Gedatolisib; Palbociclib and 2 more · For: Breast Cancer
Sites: Birmingham, Alabama; Goodyear, Arizona; Jonesboro, Arkansas · 235 sites in all
Celcuity IncIndustry
NCT02684032 · 141 participants · Start Jun 14, 2016 · Primary completion Jan 19, 2022
Drug: Gedatolisib; Palbociclib and 2 more · For: Breast Cancer
Sites: Birmingham, Alabama; Corona, California; Fountain Valley, California · 41 sites in all
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT03675893 · 110 participants (planned) · Start Dec 24, 2018 · Primary completion Aug 1, 2028
Drug: Letrozole; Abemaciclib and 3 more · For: Endometrial Cancer
Sites: Boston, Massachusetts · 3 sites in all
PfizerPfizer (PFE)
NCT01920061 · 110 participants · Start Sep 10, 2013 · Primary completion Jan 8, 2020
Drug: PF-05212384 (gedatolisib); Docetaxel and 2 more · For: Neoplasm
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 29 sites in all
PfizerPfizer (PFE)
NCT01347866 · 105 participants · Start Oct 2011 · Primary completion Dec 2015
Drug: PF-05212384; PD-0325901 and 2 more · For: Advanced Cancer
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 18 sites in all
- Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid TumorsCompleted
PfizerPfizer (PFE)
NCT00940498 · 78 participants · Start Jan 2010 · Primary completion Aug 2011
Drug: PF-05212384 (also known as PKI-587) · For: Neoplasms
Sites: Boston, Massachusetts; Rochester, Minnesota; New York, New York · 9 sites in all
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT03065062 · 75 participants (planned) · Start Feb 28, 2017 · Primary completion Dec 31, 2026
Drug: Palbociclib; Gedatolisib · For: Lung Cancer Squamous Cell; Solid Tumors; Head & Neck Cancer and 1 more
Sites: Boston, Massachusetts · 3 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hyperglycaemia7
- anaemia5
- drug ineffective4
- escherichia bacteraemia4
- leukopenia4
- pyrexia4
- pulmonary embolism2
- cellulitis1
- colitis1
- embolism1
- hyperbilirubinaemia1
- mania1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 5 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
Hurvitz SA, Layman RM, Curigliano G, et al. · J Clin Oncol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM, Han HS, Rugo HS, et al. · Lancet Oncol 2024 · Multicenter Study, Clinical Trial, Phase I
- Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Wesolowski R, Rugo HS, Specht JM, et al. · Clin Cancer Res 2025 · Clinical Trial, Phase I
- Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion.
Houk BE, Alvey CW, Visswanathan R, et al. · Clin Pharmacol Drug Dev 2019 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Curigliano G, Shapiro GI, Kristeleit RS, et al. · Br J Cancer 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers.
Phadke S, Miller KD, Shah A, et al. · Breast Cancer Res Treat 2025 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Celcuity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.